Latest Financial Results News

Qube Holdings Limited has announced a fully franked ordinary dividend of AUD 0.057 per share for the six months ending June 2025, signaling steady shareholder returns amid a stable operational period.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

Megaport Limited reported a 16% revenue increase to $227.1 million in FY25, alongside a 20% rise in Annual Recurring Revenue, while posting a slight net loss of $0.3 million. The company expanded its global footprint and launched innovative new services, setting the stage for continued growth in FY26.

Downer EDI reported a mixed FY2025 with a slight revenue decline but a striking surge in profits and earnings per share, declaring a 14.1 cent final dividend.

EQT Holdings Limited reported a robust FY25 with a 60% jump in net profit and record funds under management, while completing a major acquisition integration and raising dividends.

Ridley Corporation Limited reported a solid FY25 with revenue up 3.1% to $1.3 billion and net profit after tax rising 8.7% to $43.3 million. The company declared a fully franked final dividend of 5.00 cents per share, signaling confidence in its diversified growth strategy.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Pengana International Equities reported a solid $33.8 million profit for FY2025 and unveiled a strategic plan to diversify into global private credit, aiming to increase dividends by over half and shift to monthly payments.

Charter Hall Group delivered robust full-year 2025 results, marked by operating earnings growth and a strengthened funds management portfolio. The group projects continued momentum into FY26 with increased earnings and distribution guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

Charter Hall Group reported a mixed FY25 financial performance, with revenue declining but operating earnings and dividends increasing, highlighting resilience amid challenges.